Illumina Inc ILMN:NASDAQ

Last Price$294.86Cboe Real-Time Last Sale as of 11:22AM ET 9/25/20
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+8.55(2.99%)
Bid (Size)$294.19 (10)
Ask (Size)$294.91 (200)
Day Low / High$279.99 - 296.51
Volume1.3 M

View Biotechnology IndustryPeer Comparison as of 09/25/2020


Illumina Inc ( NASDAQ )

Price: $294.86
Change: +8.55 (2.99%)
Volume: 1.3 M
11:22AM ET 9/25/2020

Biogen Inc ( NASDAQ )

Price: $268.70
Change: -1.34 (0.50%)
Volume: 149.4 K
11:22AM ET 9/25/2020

Seattle Genetics Inc ( NASDAQ )

Price: $181.76
Change: +2.33 (1.30%)
Volume: 134.2 K
11:16AM ET 9/25/2020

Agilent Technologies Inc ( NYSE )

Price: $97.20
Change: +0.86 (0.89%)
Volume: 176.7 K
11:18AM ET 9/25/2020

Moderna Inc ( NASDAQ )

Price: $68.49
Change: +1.33 (1.98%)
Volume: 3.9 M
11:23AM ET 9/25/2020

Read more news Recent News

Analysts' Raise Illumina's 2020, 2021 Earnings Estimates
12:15AM ET 9/24/2020 MT Newswires

Illumina Inc's (NASDAQ:ILMN, Recent Price: 273.00) full year forecasted earnings estimates for 2020 and 2021 have been increased. The consensus for 2020,...

Research Alert: CFRA Maintains Hold Opinion On Shares Of Illumina, Inc
12:10PM ET 9/22/2020 MT Newswires

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...

Analyst Actions: Wells Fargo Adjusts Illumina's Price Target to $250 From $290, Maintains Underweight Rating
10:14AM ET 9/22/2020 MT Newswires

Illumina (ILMN) has an average rating of hold and price targets ranging from $220 to $390, according to analysts polled by Capital IQ. (MT Newswires covers...

Analyst Actions: Canaccord Genuity Lowers Illumina's Price Target to $300 From $350, Maintains Hold Rating
10:13AM ET 9/22/2020 MT Newswires

Illumina (ILMN) has an average rating of hold and price targets ranging from $220 to $390, according to analysts polled by Capital IQ. (MT Newswires covers...

View all Commentary and Analysis

Stock Market News for Sep 25, 2020
7:53AM ET 9/25/2020 Zacks

Benchmarks closed in the positive territory on Thursday as tech stocks recovered some of the recent...

Exelixis Cabozantinib Data, And Other News: The Good, Bad And Ugly Of Biopharma
1:55AM ET 9/25/2020 Seeking Alpha

ANIK vs. ILMN: Which Stock Should Value Investors Buy Now?
10:40AM ET 9/24/2020 Zacks

ANIK vs. ILMN: Which Stock Is the Better Value Option?

Beating COVID-19 With The Pacer BioThreat Strategy ETF (Podcast)
7:00AM ET 9/24/2020 Seeking Alpha

Company Profile

Business DescriptionIllumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA. View company web site for more details
Address5200 Illumina Way
San Diego, California 92122
Number of Employees7,300
Recent SEC Filing09/22/2020425
President, Chief Executive Officer & DirectorFrancis A. deSouza
Senior Vice President-Global Quality & OperationsRobert P. Ragusa
Chief Financial Officer & Senior Vice PresidentSam A. Samad
Chief Medical OfficerPhillip G. Febbo

Company Highlights

Price Open$284.43
Previous Close$286.31
52 Week Range$196.78 - 404.20
Market Capitalization$43.0 B
Shares Outstanding146.0 M
SectorHealth Technology
Next Earnings Announcement10/22/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings63.14
Earnings per Share$4.43
Beta vs. S&P 500N/A
Revenue$3.3 B
Net Profit Margin20.67%
Return on Equity15.19%

Analyst Ratings as of 09/21/2020

Consensus RecommendationConsensus Icon
Powered by Factset